To date, few cases of therapy‐related leukemia have been reported in long‐term follow‐up studies of BRCA1 and BRCA2 mutation carriers, but these studies have been limited by significant loss to follow‐up, a critical problem for identifying a toxicity that can occur up to 10 years later.17, 18, 19 Thus, longer term hematologic toxicity differences remain an open question and require further study. Here, BRCA1 is linked to leukemia.